The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z.
Jain P, et al.
Br J Haematol. 2018 Jan;180(1):33-40. doi: 10.1111/bjh.15018. Epub 2017 Nov 21.
Br J Haematol. 2018.
PMID: 29164608
Free PMC article.